Mycobacterium avium complex (MAC) Immune Reconstitution Syndrome (IRIS) With Reduced Susceptibility to Ethambutol in an HIV-Infected Patient

Annals of Pharmacotherapy

Volumn 48, Issue 9, 2014, Pages 1219-1224

  Adams, Immaculata B ^a   Schafer, Jason J ^a   Roberts, Amity L ^b   Short, William R ^b  

^a Jefferson School of Pharmacy   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ethambutol; HIV; immune reconstitution syndrome; IRIS; MAC; Mycobacterium avium complex; Mycobacterium avium complex with IRIS; nontuberculosis mycobacteria; rifabutin

Indexed keywords

ANTIVIRUS AGENT; AZITHROMYCIN; COBICISTAT; DARUNAVIR; ELVITEGRAVIR; EMTRICITABINE; ETHAMBUTOL; RIFABUTIN; RITONAVIR; STEROID; TENOFOVIR;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIUM DETECTION; CASE REPORT; CD4 LYMPHOCYTE COUNT; CERVICAL LYMPHADENOPATHY; CYTOMEGALOVIRUS RETINITIS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPH NODE BIOPSY; LYMPHATIC DRAINAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SECONDARY PREVENTION; STEROID THERAPY; TUBERCULOUS LYMPHADENITIS; VIRUS LOAD; YOUNG ADULT;

EID: 84905513598     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014536879     Document Type: Article

References (18)

1. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed December 20, 2013.
2. DeJesus E,Rockstroh JK,Henry K, et al.Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3, non-inferiority trial.Lancet. 2012;379:2429-2438.
3. Rockstroh JK,DeJesus E,Henry K.A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir df vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir df for initial treatment of HIV-1 infection: analysis of week 96 results.J Acquir Immune Defic Syndr. 2013;62:483-486.
4. van Ingen J,Egelund EF,Levin A, et al.The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.Am J Respir Crit Care Med. 2012;186:559-565.
5. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013:.
6. Griffith DE,Aksamit T,Brown-Elliott BA, et al.An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.Am J Respir Crit Care Med. 2007;175:367-416.
7. Benson CA.Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome.Clin Infect Dis. 1994;18:S218-S222.
8. Phillips P,Bonner S,Gataric N, et al.Nontuberculosis mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.Clin Infect Dis. 2005;41:1483-1497.
9. Corti M,Palmero D.Mycobacterium avium complex infection in HIV/AIDS patients.Expert Rev Anti Infect Ther. 2008;6:351-363.
10. Kaplan JE,Hanson D,Dworkin MS, et al.Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy.Clin Infect Dis. 2000;30:S5-S14.
11. Gordin FM,Sullam PM,Shfran SD, et al.A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex.Clin Infect Dis. 1999;28:1080-1085.
12. Benson CA,Williams PL,Currier JS, et al.A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.Clin Infect Dis. 2003;37:1234-1243.
13. Karakousis PC,Moore RD,Chaisson RE.Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.Lancet Infect Dis. 2004;4:557-565.
14. Brown-Elliott BA,Nash KA,Wallace RJ.Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.Clin Microbiol Rev. 2012;25:545-582.
15. Shafran SD,Talbot JA,Chomye S.Does in vitro susceptibility to rifabutin and ethambutol predict response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin.Clin Infect Dis. 1998;27:1401-1405.
16. Deshpande D,Srivastava S,Meek C,Leff R,Gumbo T.Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular mycobacterium avium.Antimicrob Agents Chemother. 2010;54:1728-1733.
17. Kunin CM.Antimicrobial activity of rifabutin.Clin Infect Dis. 1996;22:S3-S14.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/Content-Files/AdultandAdole-scentGL.pdf. Accessed January 15, 2014.